These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
266 related articles for article (PubMed ID: 21737553)
1. Roflumilast with long-acting β2-agonists for COPD: influence of exacerbation history. Bateman ED; Rabe KF; Calverley PM; Goehring UM; Brose M; Bredenbröker D; Fabbri LM Eur Respir J; 2011 Sep; 38(3):553-60. PubMed ID: 21737553 [TBL] [Abstract][Full Text] [Related]
2. Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE(2)SPOND rationale and study design. Rennard SI; Martinez FJ; Rabe KF; Sethi S; Pizzichini E; McIvor A; Siddiqui S; Anzueto A; Zhu H Int J Chron Obstruct Pulmon Dis; 2016; 11():1921-8. PubMed ID: 27574416 [TBL] [Abstract][Full Text] [Related]
3. Effect of Roflumilast and Inhaled Corticosteroid/Long-Acting β2-Agonist on Chronic Obstructive Pulmonary Disease Exacerbations (RE(2)SPOND). A Randomized Clinical Trial. Martinez FJ; Rabe KF; Sethi S; Pizzichini E; McIvor A; Anzueto A; Alagappan VK; Siddiqui S; Rekeda L; Miller CJ; Zetterstrand S; Reisner C; Rennard SI Am J Respir Crit Care Med; 2016 Sep; 194(5):559-67. PubMed ID: 27585384 [TBL] [Abstract][Full Text] [Related]
4. Pooled subpopulation analyses of the effects of roflumilast on exacerbations and lung function in COPD. Hanania NA; Calverley PM; Dransfield MT; Karpel JP; Brose M; Zhu H; Goehring UM; Rowe P Respir Med; 2014 Feb; 108(2):366-75. PubMed ID: 24120253 [TBL] [Abstract][Full Text] [Related]
5. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Calverley PM; Sanchez-Toril F; McIvor A; Teichmann P; Bredenbroeker D; Fabbri LM Am J Respir Crit Care Med; 2007 Jul; 176(2):154-61. PubMed ID: 17463412 [TBL] [Abstract][Full Text] [Related]
6. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. Martinez FJ; Calverley PM; Goehring UM; Brose M; Fabbri LM; Rabe KF Lancet; 2015 Mar; 385(9971):857-66. PubMed ID: 25684586 [TBL] [Abstract][Full Text] [Related]
7. Does roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? The REACT study protocol. Calverley PM; Martinez FJ; Fabbri LM; Goehring UM; Rabe KF Int J Chron Obstruct Pulmon Dis; 2012; 7():375-82. PubMed ID: 22791991 [TBL] [Abstract][Full Text] [Related]
8. Phosphodiesterase 4 inhibitors augment the ability of formoterol to enhance glucocorticoid-dependent gene transcription in human airway epithelial cells: a novel mechanism for the clinical efficacy of roflumilast in severe chronic obstructive pulmonary disease. Moodley T; Wilson SM; Joshi T; Rider CF; Sharma P; Yan D; Newton R; Giembycz MA Mol Pharmacol; 2013 Apr; 83(4):894-906. PubMed ID: 23389862 [TBL] [Abstract][Full Text] [Related]
9. [Roflumilast in combination with long-acting bronchodilators in the management of patients with severe and very severe COPD. A cost-effectiveness analysis for Germany]. Nowak D; Ehlken B; Kotchie R; Wecht S; Magnussen H Dtsch Med Wochenschr; 2013 Jan; 138(4):119-25. PubMed ID: 23322425 [TBL] [Abstract][Full Text] [Related]
11. Functional respiratory imaging to assess the interaction between systemic roflumilast and inhaled ICS/LABA/LAMA. Vos W; Hajian B; De Backer J; Van Holsbeke C; Vinchurkar S; Claes R; Hufkens A; Parizel PM; Bedert L; De Backer W Int J Chron Obstruct Pulmon Dis; 2016; 11():263-71. PubMed ID: 26917956 [TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of roflumilast in combination with bronchodilator therapies in patients with severe and very severe COPD in Switzerland. Samyshkin Y; Schlunegger M; Haefliger S; Ledderhose S; Radford M Int J Chron Obstruct Pulmon Dis; 2013; 8():79-87. PubMed ID: 23386787 [TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of roflumilast as an add-on treatment to long-acting bronchodilators in the treatment of COPD associated with chronic bronchitis in the United Kingdom. Samyshkin Y; Kotchie RW; Mörk AC; Briggs AH; Bateman ED Eur J Health Econ; 2014 Jan; 15(1):69-82. PubMed ID: 23392624 [TBL] [Abstract][Full Text] [Related]
15. Roflumilast: a novel treatment for chronic obstructive pulmonary disease. Reid DJ; Pham NT Ann Pharmacother; 2012 Apr; 46(4):521-9. PubMed ID: 22433610 [TBL] [Abstract][Full Text] [Related]
16. Roflumilast added to triple therapy in patients with severe COPD: a real life study. Muñoz-Esquerre M; Diez-Ferrer M; Montón C; Pomares X; López-Sánchez M; Huertas D; Manresa F; Dorca J; Santos S Pulm Pharmacol Ther; 2015 Feb; 30():16-21. PubMed ID: 25445930 [TBL] [Abstract][Full Text] [Related]
20. Can roflumilast, a phosphodiesterase-4 inhibitor, improve clinical outcomes in patients with moderate-to-severe chronic obstructive pulmonary disease? A meta-analysis. Luo J; Wang K; Liu D; Liang BM; Liu CT Respir Res; 2016 Feb; 17():18. PubMed ID: 26887407 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]